Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Herchenhorn, Daniel; Dias, Fernando Luiz; Viégas, Célia M.; Federico, Miriam Hatsue Honda; Araújo, Carlos; Small, I. A.; Bezerra, M.; Fontão, K.; Knust, Renata; Ferreira, Carlos Gil; Martins, Renato

doi:10.1016/j.ijrobp.2009.08.079

Cited by 39 publications

(18 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of erlotinib did not increase treatment toxicity in patients with LA-HNSCC, but failed to significantly increase the complete response rate (52 vs. 40% for P-RT and P-RT plus erlotinib, respectively) or PFS (HR = 0.9; p = 0.71)[. ]Lapatinib (GW572016), another TKI, was also studied in patients with LAHNC with preliminary evidence of clinical activity [88]. …”

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. Its treatment is complex and evolving. In general, early-stage disease may be managed with single-modality treatment while an advanced stage (about 60% of clinical presentation) needs a multidisciplinary approach. In this setting concurrent chemoradiation has been associated with improvement in locoregional control and organ preservation, but at the cost of significant acute and chronic toxicity. Molecular target therapies specially directed to epidermal growth factor receptor (EGFR) might improve the outcomes and reduce toxicities. In recurrent-metastatic (R/M) HNSCC, cetuximab, a monoclonal antibody against EGFR, plus platinum-based chemotherapy (CT) allow an overall survival (OS) of about 10 months. However, the prognosis for R/M-HNSCC remains dismal and additional efforts are needed. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, data on induction CT, anti-EGFR inhibitors, innovative molecular targets and predictor factors were reported. Further results on target therapies were presented at the European Cancer Congress (ECC) 2013, where a large study also showed that hyperfractionated radiotherapy (RT) improve OS rates compared with standard RT. The aim of this review is to discuss current standards and emerging therapies by considering recent new updates.

show abstract

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

show abstract

“…This study concluded that this combination (erlotinib plus cisplatin plus radiotherapy) is safe and effective and deserves further investigations. [31] BCR-ABL inhibitors Imatinib was one of the first targeted therapies to be developed for the treatment of chronic myeloid leukemia. It blocks the BCR-ABL protein kinase that results from a chromosomal translocation (the Philadelphia chromosome) in chronic myeloid leukemia.…”

Section: Gefitinibmentioning

confidence: 99%

Specific role of targeted molecular therapy in treatment of oral squamous cell carcinoma

Gupta¹,

Sivasankari²

2017

Oncobiology and Targets

View full text Add to dashboard Cite

Oral cancer is a potentially fatal disease that constitutes an important portion of tumors that occur in the head and neck region. Oral cancer can affect overall and mental health, appearance, employment, social life, and family living. The disease can cause serious changes in the functioning of the upper aero digestive tract that affects the quality of life in patients. The use of conventional treatment modalities (surgery, radiation, and/or chemotherapy) depends on tumor respectability and location as well as whether an organ preservation approach is feasible. However, their role in oral cancer treatment is nonselective and can cause damage to normal tissue. In particular, chemo radiotherapy is associated with systemic toxicities that often reduce patient compliance and prevent timely completion of therapy. The development of targeted therapies to target select pathways involved in carcinogenesis, potentially decrease systemic toxicities and morbidities associated with cancer burden and hence improve the prognosis in cancer patients. In the present article, the role of various targeted molecules in the treatment of oral cancer is discussed.

show abstract

“…In a phase I/II study involving 37 patients with locally advanced SCCHN, erlotinib administered in combination with cisplatin and radiotherapy was associated with a RR of 74% (all complete responses [CRs]) and 3-year PFS and OS rates of 61 and 72%, respectively [58]. The most common nonhematologic AEs were nausea/vomiting, dysphagia, and stomatitis.…”

Section: Future Directions Beyond Cetuximab: Inhibiting the Erbb Familymentioning

confidence: 99%

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Agulnik

2012

Med Oncol

View full text Add to dashboard Cite

Despite recent advances in radiotherapy and chemotherapy, survival rates for squamous cell carcinoma of the head and neck (SCCHN) have remained poor. The focus of SCCHN therapy has more recently shifted to the molecular level, particularly the epidermal growth factor receptor (EGFR/ErbB) pathway. Several agents that target the EGFR pathway, including monoclonal antibodies and tyrosine kinase inhibitors, are under investigation for SCCHN. Searches of PubMed and results of key oncology congresses were performed to identify relevant articles and abstracts. The EGFR-targeted monoclonal antibody cetuximab is approved for the treatment of locally advanced SCCHN in combination with radiotherapy, for first-line treatment of recurrent or metastatic SCCHN in combination with platinum-based chemotherapy and 5-fluorouracil, and for recurrent or metastatic SCCHN following progression with platinum-based chemotherapy. Other investigational EGFR-targeted monoclonal antibodies (e.g., panitumumab, nimotuzumab, zalutumumab) are in clinical development for SCCHN. Inhibition of the tyrosine kinase domain of EGFR has also been explored as a therapeutic approach in SCCHN using small-molecule reversible inhibitors, such as gefitinib and erlotinib. However, a key challenge in SCCHN is the development of resistance, and strategies are being pursued to delay or overcome resistance to EGFR-targeted agents. These strategies include development of agents that inhibit multiple ErbB receptors simultaneously (e.g., lapatinib) or that bind multiple ErbB family receptors irreversibly (e.g., afatinib, PF-00299804) and investigation of combinations of agents that target multiple pathways implicated in the pathogenesis of SCCHN. Ongoing large clinical trials are evaluating these emerging agents and combinations for the treatment of SCCHN.

show abstract

Phase I/II Study of Erlotinib Combined With Cisplatin and Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Cited by 39 publications

References 39 publications

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Specific role of targeted molecular therapy in treatment of oral squamous cell carcinoma

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Contact Info

Product

Resources

About